__timestamp | Grifols, S.A. | MiMedx Group, Inc. |
---|---|---|
Wednesday, January 1, 2014 | 1699214000 | 105558000 |
Thursday, January 1, 2015 | 1930998000 | 167094000 |
Friday, January 1, 2016 | 1912291000 | 212608000 |
Sunday, January 1, 2017 | 2152011000 | 285920000 |
Monday, January 1, 2018 | 2049560000 | 322725000 |
Tuesday, January 1, 2019 | 2341232000 | 256174000 |
Wednesday, January 1, 2020 | 2255165000 | 208904000 |
Friday, January 1, 2021 | 1962596000 | 215332000 |
Saturday, January 1, 2022 | 2231530000 | 219525000 |
Sunday, January 1, 2023 | 2322701000 | 266843000 |
Data in motion
In the ever-evolving landscape of the healthcare industry, understanding financial performance is crucial. This analysis delves into the gross profit trends of two prominent companies: Grifols, S.A. and MiMedx Group, Inc., from 2014 to 2023.
Grifols, S.A. has shown a consistent upward trajectory in gross profit, with a notable increase of approximately 37% over the decade. The company peaked in 2019 and 2023, reflecting its robust market strategies and adaptability.
MiMedx Group, Inc. experienced a more volatile path, with a remarkable 206% growth from 2014 to 2018. Despite fluctuations, the company maintained a steady rise, showcasing resilience and innovation.
This comparative analysis highlights the strategic differences and market positioning of these two industry players, offering valuable insights for investors and stakeholders.
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Annual Comparison of SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline
5 Year Trend in Average Market Capitalization for AbbVie
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Number of Employees for Top 10 Healthcare Companies
Number of Employees for Top 10 Pharma Companies
Average Market Capitalization of Abbvie Annually
5 Year Trend in Market Capitalization for AbbVie
5 Year Trend in Average Market Capitalization for AbbVie
Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters